Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Psychopharmacol Bull ; 34(1): 9-12, 1998.
Article in English | MEDLINE | ID: mdl-9564192

ABSTRACT

We attempted to develop and validate a computer-driven patient self-rated questionnaire [COSAPSQ] which should provide a reliable, rapid, and inexpensive method to assess symptom severity in patients with psychosis in general and with schizophrenia in particular. After giving informed consent patients with DSM-IV schizophrenia or schizoaffective disorder were interviewed and rated on PANSS and CGI. Subsequently patients completed the COSAPSQ questionnaire (61 multiple choice questions) in the presence of an observer. The analysis of the first 29 rating sets showed that patients with CGI scores of 3-6 completed the questionnaire in a mean time of 21.6 minutes. One-way analysis of variance of COSAPSQ total scores by CGI ratings was highly significant (p < .001). COSAPSQ total scores correlated well with PANSS total, general and positive scores and with CGI (all r = 6-.7; p < .005). The next versions of the questionnaire will require some adjustments: overall fewer questions, improved assessment of negative symptoms, and improved graphic presentation.


Subject(s)
Schizophrenia/diagnosis , Adult , Humans , Male , Psychiatric Status Rating Scales , Schizophrenic Psychology , Self-Assessment , Surveys and Questionnaires
2.
Psychopharmacol Bull ; 34(1): 71-4, 1998.
Article in English | MEDLINE | ID: mdl-9564201

ABSTRACT

Atypical neuroleptics present a unique opportunity to examine confounding by neuroleptic-induced extrapyramidal symptoms (EPS) in the assessment of negative signs of schizophrenia. EPS, such as facial bradykinesia and akinesia, involve some of the same response systems and phenomena as emotional display channels. EPS are attributed to the blockade of dopamine receptors in the striatum by traditional neuroleptics. Newer atypical neuroleptics target primarily mesolimbic and mesocortical areas, and receptors for other transmitters such as serotonin. Olanzapine has been reported as less likely to cause EPS and may improve some negative signs. We investigated the relationship between measures of EPS and negative symptoms in patients with schizophrenia treated with haloperidol or olanzapine. Patients were rated with the Positive and Negative Syndrome Scale (PANSS) and the Simpson-Angus Scale EPS scale. Results show that the two agents have comparable efficacy but different safety outcomes. A positive correlation between EPS and PANSS negative score was detected in the haloperidol group only. Stepwise multiple regression analysis shows that a big proportion of variability in PANSS negative symptoms is predicted by EPS in the haloperidol group, but not in the olanzapine group, even though EPS increased in patients treated with haloperidol but not in olanzapine patients.


Subject(s)
Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Basal Ganglia Diseases/chemically induced , Haloperidol/adverse effects , Haloperidol/therapeutic use , Pirenzepine/analogs & derivatives , Schizophrenia/drug therapy , Adult , Aged , Benzodiazepines , Humans , Male , Middle Aged , Olanzapine , Pirenzepine/adverse effects , Pirenzepine/therapeutic use , Psychiatric Status Rating Scales , Schizophrenic Psychology
3.
J Nerv Ment Dis ; 184(10): 589-97, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8917155

ABSTRACT

The present study investigated flat affect in schizophrenia within a multicomponent model of emotions in which affects were identified with the expression or display of feelings. Display, as well as other components of emotion, such as subjective experience and psychophysiological reactivity, were examined as 24 schizophrenic inpatients (12 with flat affect) and 12 depressed inpatients were guided through imagery of personal emotional experiences. It was hypothesized that display variables would show a relationship with flat affect, whereas physiological and subjective variables would not. Increased flatness of affect was associated with longer pauses and reduced dyadic interaction and less zygomatic (cheek) electromyogram activity. The flat affect patients unexpectedly showed more corrugator (brow) electromyogram activity compared with the depressed group, which perhaps reflects difficulty in self-expression. The flat affect group had faster heart rates at baseline. The groups did not, however, differ in self-report of the intensity of experienced emotion. These results support the view that flat affect patients show a reduction in emotional display, whereas other subsystems of emotion processing appear normally engaged.


Subject(s)
Emotions/physiology , Schizophrenia/diagnosis , Schizophrenic Psychology , Adult , Affect/physiology , Blood Volume , Depressive Disorder/diagnosis , Depressive Disorder/physiopathology , Diagnosis, Differential , Electromyography , Facial Muscles/physiology , Female , Heart Rate/physiology , Hospitalization , Humans , Male , Middle Aged , Pulse/physiology , Schizophrenia/physiopathology
4.
J Clin Psychiatry ; 57(10): 455-9, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8909331

ABSTRACT

BACKGROUND: This study assessed the safety and efficacy of nadolol 120 mg/day compared with placebo, when administered adjunctively to neuroleptic in a group of acutely aggressive schizophrenic patients. METHOD: Thirty-four male patients enrolled in this double-blind, placebo-controlled trial. The subjects were evaluated with the Brief Psychiatric Rating Scale (BPRS) and the Simpson Angus Neurologic Rating Scale for extrapyramidal effects. The total BPRS score as well as three factors, thought disturbance, hostility, and activation, was analyzed. RESULTS: Compared with those who received placebo, the patients taking nadolol showed significant improvement on total BPRS score, particularly on the thought disturbance and activation factors, after the first treatment week (p = .05). By the end of the second treatment week, the patients taking placebo also began to show improvement, and the group differences were no longer significant. The patients treated with nadolol showed significantly more improvement on Simpson-Angus scores than those who received placebo (p = .03). However, there was no significant correlation between BPRS and Simpson-Angus changes. In the nadolol group, patients with and without akathisia showed no significant difference in their BPRS scores. CONCLUSION: These findings suggest that adjunctive nadolol may be useful in the treatment of acutely aggressive schizophrenic patients by inducing a more rapid and consistent decrease of overall psychiatric symptoms and by reducing the extrapyramidal effects. Our results raise the possibility that the mechanism of action of nadolol on psychiatric symptoms in schizophrenic patients may be different from the mechanism of improvement of neuroleptic-induced extrapyramidal symptoms and akathisia. Nadolol may be a helpful adjunctive treatment for schizophrenic patients in general and not just for those with a high hostility level.


Subject(s)
Aggression/drug effects , Antipsychotic Agents/therapeutic use , Nadolol/therapeutic use , Schizophrenia/drug therapy , Acute Disease , Adult , Double-Blind Method , Drug Therapy, Combination , Humans , Intensive Care Units , Male , Nadolol/pharmacology , Placebos , Psychiatric Department, Hospital , Psychiatric Status Rating Scales , Schizophrenia/diagnosis , Schizophrenic Psychology , Treatment Outcome
5.
Biofeedback Self Regul ; 16(2): 117-29, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1677276

ABSTRACT

The efficacy of electromyographic feedback training in reducing the magnitude and frequency of the oral-lingual movements associated with tardive dyskinesia (TD) was investigated in a groups design. Twenty adult male inpatients diagnosed as having TD using the Abnormal Involuntary Movements Scale (AIMS) were randomly assigned to one of two treatment conditions. Following identification, all participants were initially reduced to the lowest effective dosage of neuroleptics, and then discontinued from anticholinergics. Following one month on this regimen, they were given a course of feedback training consisting of ten 14-minute sessions. Group one participants were provided with a tone contingent upon oral-lingual movements above a yoked threshold. Group two participants were given noncontingent feedback tones generated randomly. Weekly AIMS were administered as well as an initial baseline during each session to determine current level of oral-lingual activity. An analysis of session effects indicated significantly more suppression of oral-lingual activity in the contingent group versus the noncontingent feedback group. Jaw and forehead activity also measured showed reductions of similar magnitudes for both groups.


Subject(s)
Biofeedback, Psychology , Dyskinesia, Drug-Induced/therapy , Electromyography , Aged , Antipsychotic Agents/adverse effects , Dyskinesia, Drug-Induced/physiopathology , Dyskinesia, Drug-Induced/psychology , Humans , Male , Middle Aged , Psychiatric Status Rating Scales
6.
Brain Lang ; 28(1): 141-53, 1986 May.
Article in English | MEDLINE | ID: mdl-3719294

ABSTRACT

The effects of hypnosis and imagery training on the naming behavior of three subjects with Broca's aphasia were investigated using a multiple baseline design across subjects. Treatment consisted of the induction of hypnosis, followed by guided imagery focused on the physical and functional attributes of stimulus objects. Measures of naming ability on both trained and untrained items were taken at baseline, after every training session, and a few hours after training each day. Measures were also taken of imagery ability, hypnotic susceptibility, and psychological state. Results indicated that treatment facilitated improvement in naming ability, over baseline level, for two subjects. In the case of the third subject, the verbal label was incorporated into the imagery procedure following 10 training sessions. Subsequently, this subject's naming behavior improved over baseline level. The results are discussed in terms of current theory and research in neuropsychology and cognitive psychology.


Subject(s)
Anomia/therapy , Aphasia, Broca/therapy , Aphasia/therapy , Hypnosis , Imagination , Aphasia, Broca/psychology , Female , Humans , Male , Middle Aged , Neuropsychological Tests
7.
St Tomas Nurs J ; 7(2): 46-58, 1969 Feb.
Article in English | MEDLINE | ID: mdl-5196583
SELECTION OF CITATIONS
SEARCH DETAIL
...